This website uses cookies to improve your browsing experience.
By continuing to use this website you consent to the use of cookies in accordance with our cookie policy. To find out more, click on this link: Read More Allow Cookies

Wednesday 31 January 2018

Ronan Daly Jermyn advises Agilent Technologies on its acquisition of Luxcel Biosciences Limited

Ronan Daly Jermyn advised Agilent Technologies (NYSE: A) on its acquisition of Cork-based Luxcel Biosciences Limited. The acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.

Headquartered in California, Agilent Technologies is a global leader in life sciences, diagnostics and applied chemical markets. The company generated revenues of $4.47 billion in fiscal 2017 and employs 13,500 people worldwide.

Founded as a spin-out company from University College Cork, Luxcel is a provider of cost effective and easy-to-use fluorescence-based in vitro cell test kits, targeting cell metabolism, bioenergetics and drug toxicity applications.

Cork-based corporate partner Diarmaid Gavin led the RDJ deal team, assisted by associate Colm Manning and solicitor Sarah Slevin.  Advices on employment and tax aspects were provided by partner Deirdre Malone and associate Mark Ludlow respectively.

Letter footer for printed documents
© 2018 Ronan Daly Jermyn
Web design by Granite Digital